One of the questions we are asked about assay transfer is if the quality control analysts should be involved in early assay development or if it is better to engage them when the assay is more mature and ready for transfer? Listen to how Heather Malicki, Ph.D. responded to this question on our June 6th webinar titled Mastering the Journey from Initial Method Transfer to Successful Lot Release for Cell & Gene Therapies. https://lnkd.in/exTtekXm
WuXi Advanced Therapies
Biotechnology Research
Philadelphia, Pennsylvania 14,340 followers
An integrated cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO)
About us
WuXi Advanced Therapies - Accelerating Progress and Time to Market WuXi Advanced Therapies is a cell and gene therapy Contract Testing, Development and Manufacturing Organization (CTDMO) that is reducing the complexities of manufacturing by providing integrated platforms that enable cell and gene therapies to be developed, manufactured, and released faster and with greater predictability. Our Story By leveraging platforms and integrated testing our team provides expedited development and commercialization of cell, gene, protein and viral-based therapies. This approach enables new biopharmaceuticals to be developed, manufactured and released faster and with greater predictability, thereby reducing the complexities of high-touch, multi-vendor production models. Our solutions help clients overcome challenges to commercialization, including process development, manufacturing capacity, analytical development, and raw materials management. Multiple, scale-able, enabling platforms integrate manufacturing, process development and testing capabilities to provide greater predictability and speed to clinic. We support advanced therapy programs with extensive infrastructure and 400,000 square feet of state-of-the-art, GMP-compliant facilities on our modern campus located at the Navy Yard in Philadelphia, Pennsylvania.
- Website
-
https://advancedtherapies.com
External link for WuXi Advanced Therapies
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Philadelphia, Pennsylvania
- Type
- Privately Held
- Founded
- 2004
- Specialties
- Cell Therapy, Gene Therapy, Process Development, Cell Banking, Virology, Autologous , Allogeneic, Therapeutics, CAR-T, CDMO, CMO, Contract Manufacturing, Therapeutics, Biomanufacturing, Bioprocessing, Antibody Drug Conjugate, Viral Vector, Biotechnology, Protein Therapeutic, Viral Clearance, Biologics, Biotherapeutics, Immunotherapy, Laboratory Testing, Preclinical Safety, Cell Line Characterization, Adventitious Agent Testing, Product Packaging, Lot Release, Analytical Development, Vaccine Manufacturing, Extractables & Leachables, AAV, LENTI, and CAR-T
Locations
-
Primary
Get directions
4701 League Island Blvd
Philadelphia, Pennsylvania 19112, US
-
Get directions
4751 League Island Blvd
Philadelphia, Pennsylvania 19112, US
-
Get directions
4000 S 26th St
Philadelphia, Pennsylvania 19112, US
-
Get directions
400 Rouse Blvd.
Philadelphia, Pennsylvania 19112, US
Employees at WuXi Advanced Therapies
-
Mike Quinn, M.S.
Global Talent Acquisition Leader - US & EU
-
Alan Moore
Advanced Therapies Consulting and Advisory Services
-
Elise Saunders
Human Resources Director at WuXi Advanced Therapies
-
Cesar Fernandes, PMP
IT Infrastructure Management | IT Service Delivery | Team Building | Project Management
Updates
-
Therapy developers who have a product that requires a large amount of #LVV or those screening multiple GOIs can benefit from WuXi Advanced Therapies’ XOFLX™ packaging and producer cell lines. The XOFLX™ stable technology has been shown to work well across a wide array of transgenes and the integrated LVV genes have reduced homology for improved safety. #XOFLX™ packaging and producer cell lines stably express genes needed for LVV production, eliminating the need and expense of multiple plasmids. Read more online at https://lnkd.in/eHBXc-dy or contact us if you are interested in evaluating the application of custom XOFLX™ packaging or producer cell lines. After initial evaluation, you can continue to conduct in-house R&D under a Research Use Only (RUO) license or transition to in-house GMP manufacturing under a Clinical and Commercial Use License or with the help of WuXi Advanced Therapies development and manufacturing services in Philadelphia, Pennsylvania. Get in touch with the team today https://lnkd.in/eMT95ei
-
-
Our team sends out a monthly newsletter with the latest insights, tools, and data from our expert scientists and engineers. You can view this month’s issue here https://lnkd.in/etVBA5RH and visit our website at https://lnkd.in/e58HpGYB make sure it ends up in your inbox every month! 📨
-
-
On Thursday July 25th at 2pm EST WuXi Advanced Therapies, will share an update on their capabilities and capacity in Outsourced Pharma's Capacity Update for #CellandGeneTherapy. Register online here https://lnkd.in/exWXBjtg to hear from Seiga Ohmine and Audrey Chang who will present our testing, development and manufacturing capabilities.
-
-
Adeno- associated virus (#AAV) vectors are one of the vehicles available for delivering therapeutic genes to patients’ cells. However, the commercial success and accessibility of all gene therapies hinges on overcoming significant challenges in scalability and testing. Download this short article entitled Pioneering Scalable Solutions in AAV Manufacturing and Testing for Gene Therapy to learn more about how WuXi Advanced Therapies is addressing these challenges. https://lnkd.in/egzK4N8n
-
Meet Audrey Chang! Audrey is Executive Director, CMC Scientific Advisor at WuXi Advanced Therapies. She provides expert guidance on bioanalytical testing for biologics including vaccines, mAbs, recombinant proteins, gene, and cell therapy products. Dr. Chang is well versed in all the testing services conducted at our Philadelphia campus. Our testing operations are co-located at the #NavyYard with our development and manufacturing teams. Please message us to schedule time to consult with Audrey about the unique needs of your program or contact us on our website at https://lnkd.in/eMT95ei
-
-
Are you at #BayOConnect Forum for Biotech & Life Sciences in #Munich? Dr. Cristina I. Ureche is on site and happy to connect! Stop by the WuXi AppTec booth and ask for her, message her directly or request a meeting online at https://lnkd.in/eAKzGGJu
-
-
WuXi Advanced Therapies has a significant track record of successfully manufacturing GMP grade cell banks and will seamlessly integrate the testing and characterization of your bank with a unified team overseeing and coordinating all milestones and activities under a single work order and contract. Download our brochure at https://lnkd.in/e9jNC4Ks to learn more and get in touch to discuss your next bank!
-
-
We are proud of our roots in #Philadelphia and our campus in the #NavyYard and thrilled to see the leadership position the Greater Philadelphia Area is taking in the industry. If you’d like to learn more, The Chamber of Commerce for Greater Philadelphia recently released a report entitled Leading the Way: Cell and Gene Therapy in Greater Philadelphia which includes the following highlights: 🏢 There are an estimated 500 CGT companies worldwide and #GreaterPhiladelphia is home to 60 including 5 of the Top 100 “companies to watch” 👨🔬 👩🔬 More than 7,000 are employed by institutions and CGT companies 🏦 Second ranked region for NIH funded Cell and Gene Therapy combined and the clear leader in Gene Therapy 🔬 Leader in translational science – Top 5 location for Phase I and II trials in both novel Cell and Gene Therapies Read the full report! https://lnkd.in/dNEguj2j
New Report Documents Momentum in Greater Philadelphia’s Cell and Gene Therapy Ecosystem
https://chamberphl.com